Expression and in vitro function of anti-PD-L1 human antibody expressed in plant

被引:5
作者
Lee, Chae Eun [1 ]
Lee, Jeong Hwan [1 ]
Chung, Hyun Joo [1 ]
Lee, Da Won [1 ]
Lim, Jong Seok [1 ]
Kim, Kibum [3 ]
Kim, Jin Wook [4 ,5 ]
Lee, Yong Seong [4 ]
Kim, Kyung Soo [6 ]
Min, Hyun Jin [6 ]
Ko, Kisung [2 ,3 ]
Myung, Soon Chul [1 ,2 ]
机构
[1] Chung Ang Univ, Coll Med, Dept Urol, Seoul, South Korea
[2] Chung Ang Univ, Mol Biodesign Res Ctr, Seoul, South Korea
[3] Chung Ang Univ, Coll Med, Dept Med, Therapeut Prot Engn Lab, Seoul, South Korea
[4] Chung Ang Univ, Dept Urol, Gwangmyeong Hosp, Gyeonggi Do, South Korea
[5] Chung Ang Univ, Coll Med, Dept Med Informat, Seoul, South Korea
[6] Chung Ang Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Anti-PD-L1; antibodies; Avelumab; Immune system; Plant expression system; Therapeutic protein; VACCINES;
D O I
10.1007/s11816-023-00844-7
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Plants can be used to produce recombinant functional proteins such as antibodies and vaccines. In this study, transgenic plants were utilized to express anti-human programmed death ligand-1 (PD-L1) monoclonal antibodies (mAb(P) PD-L1) tagged with the endoplasmic reticulum retention motif KDEL. PCR and immunoblot analyses confirmed that mAb PD-L1 was expressed in transgenic plants. ELISA analysis confirmed the binding activity of mAb(P) PD-L1 to human prostate and urothelial cancer cell lines PC-3 and TCCSUP, respectively. Confocal imaging analysis demonstrated that mAb(P) PD-L1 had binding activity against human cancer cell lines similar to Avelumab (mAb(M) PD-L1). Confocal imaging analysis showed that the binding activity of mAb(P) PD-L1 to the human tonsil is comparable to mAb(M) PD-L1. These results suggest that mAb(P) PD-L1 shows functional binding activities for PD-L1(+) cancer cells. Hence, this study showed that tobacco plants can be used to produce functional anti-human PD-L1 mAbs.
引用
收藏
页码:531 / 539
页数:9
相关论文
共 50 条
[31]   Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model [J].
Contreras-Sandoval, Ana M. ;
Merino, Maria ;
Vasquez, Marcos ;
Troconiz, Inaki F. ;
Berraondo, Pedro ;
Garrido, Maria J. .
ONCOTARGET, 2016, 7 (47) :76891-76901
[32]   Canities Subita after Extreme Trauma Showing Positive Staining for Anti-PD-L1 Antibodies: A New Clue into Etiopathogenesis? [J].
Navarro-Trivino, Francisco J. ;
Ruiz-Villaverde, Ricardo ;
Manuel Ramos-Pleguezuelos, Francisco ;
Vano-Galvan, Sergio .
SKIN APPENDAGE DISORDERS, 2022, 8 (01) :65-69
[33]   PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis [J].
Gandini, Sara ;
Massi, Daniela ;
Mandala, Mario .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 :88-98
[34]   A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells [J].
David, Justin M. ;
Dominguez, Charli ;
McCampbell, Kristen K. ;
Gulley, James L. ;
Schlom, Jeffrey ;
Palena, Claudia .
ONCOIMMUNOLOGY, 2017, 6 (10)
[35]   FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model [J].
Sow, Heng Sheng ;
Benonisson, Hreinn ;
Breukel, Cor ;
Visser, Remco ;
Verhagen, Onno J. H. M. ;
Bentlage, Arthur E. H. ;
Brouwers, Conny ;
Claassens, Jill W. C. ;
Linssen, Margot M. ;
Camps, Marcel ;
van Hall, Thorbald ;
Ossendorp, Ferry ;
Fransen, Marieke F. ;
Vidarsson, Gestur ;
Verbeek, J. Sjef .
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) :345-354
[36]   Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana [J].
Song, Ilchan ;
Kang, Yang Joo ;
Kim, Dae Heon ;
Kim, Mi Kyung ;
Ko, Kisung .
BMB REPORTS, 2020, 53 (04) :229-233
[37]   Expression, function, and glycosylation of anti-colorectal cancer large single-chain antibody (LSC) in plant [J].
Lee, Jeong Hwan ;
Park, Se Ra ;
Phoolcharoen, Waranyoo ;
Ko, Kisung .
PLANT BIOTECHNOLOGY REPORTS, 2020, 14 (03) :363-371
[38]   FcgR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia [J].
Msika, Adrien ;
Mathias, Virginie ;
Boudigou, Marina ;
Chambon, Mathilde ;
Dubois, Valerie ;
Hajri, Touria ;
Lotz, Jean-Pierre ;
Massardier, Jerome ;
Descargues, Pierre ;
Gladieff, Laurence ;
Joly, Florence ;
Lebreton, Coriolan ;
Maucort-Boulch, Delphine ;
Bin, Sylvie ;
Rousset, Pascal ;
Allias, Fabienne ;
Gaillot-Durand, Lucie ;
Devouassoux-Shisheboran, Mojgan ;
Lemaitre, Nicolas ;
Alfaidy, Nadia ;
Langlois-Jacques, Carole ;
Alves-Ferreira, Marine ;
Golfier, Francois ;
You, Benoit ;
Thaunat, Olivier ;
Bolze, Pierre-Adrien ;
Koenig, Alice .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2025, 232 (04) :381e1-381e11
[39]   JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC [J].
Jerusalem, Guy ;
Chen, Franklin ;
Spigel, David ;
Iannotti, Nicholas ;
Mcclay, Edward ;
Redfern, Charles ;
Bennouna, Jaafar ;
Taylor, Matthew ;
Kaufman, Howard ;
Kelly, Karen ;
Chand, Vikram ;
Von Heydebreck, Anja ;
Verschraegen, Claire .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S252-S252
[40]   Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs) [J].
Rajan, Arun ;
Heery, Christopher ;
Mammen, Andrew ;
Pittaluga, Stefania ;
Lepone, Lauren ;
Donahue, Renee ;
Grenga, Italia ;
Schlom, Jeffrey ;
Gulley, James ;
Hassan, Raffit .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S314-S315